Jazz Pharmaceuticals shared on LinkedIn:
“In recognition of Lung Cancer Awareness Month, we are highlighting the need for continued progress in extensive-stage small cell lung cancer (SCLC), which remains one of the most aggressive and difficult-to-treat cancers, with most patients relapsing within months of initial therapy.
Learn more about how research is exploring maintenance therapy to help sustain disease control after first-line treatment.”
About Lung Cancer Awareness Month
Lung Cancer Awareness Month takes place every November and focuses on raising awareness about the disease, the importance of early detection and the need for better treatment options. During this month, Jazz Pharmaceuticals highlights the challenges of treating lung cancer, particularly extensive-stage small cell lung cancer (SCLC), and the ongoing research into treatments that could help patients maintain disease control for longer.
You may also be interested in:
- Bob Redman: Raising Awareness of Gastric and Lung Cancer – Jazz Pharmaceuticals
- What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment